You are using an older browser version. Please use a supported version for the best MSN experience.

MOLECULIN BIOTECH, INC.

NASDAQ: MBRX
1.09
-0.05
-4.39%

Sector

Healthcare

Industry

Pharmaceuticals

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of April 3, 2017, it had not generated any revenue from its operations.

 

   
   
   
   
  • Moleculin Biotech Inc

  • 5300 Memorial Dr Ste 950

  • HOUSTON, TX 77007-8274

  • US.Map

  • Phone: +1 713 3005160

  • Fax: +1 302 6365454

  • moleculin.com

Incorporated

2015

Employees

9

Insider Trades
  • Recent
  • All
Data not available
Data not available
AdChoices
AdChoices
AdChoices
image beaconimage beaconimage beacon